NSE: AJANTPHARM | BSE: 532331

Turnaround Potential

Download real time

3014.90 66.10 (2.24%)

New 52W High today

147.9K NSE+BSE Volume

NSE 25 Feb, 2026 2:33 PM (IST)

37,659.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

01 Feb 2026

3014.90

2.24%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 16 new launches over the last 9-12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 9-12 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launches. Asia branded on the other hand witnessed...

Ajanta Pharma Ltd. has an average target of 3120.83 from 6 brokers.

Ajanta Pharma Ltd.

31 Jan 2026

3014.90

2.24%

Ajanta Pharma (BUY): Healthy earnings momentum to continue

Buy: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 7%/12% and 5.6% above our estimates driven by beat across regions. EBITDA margin 130 bps above our estimates

Ajanta Pharma Ltd. has an average target of 3120.83 from 6 brokers.

Ajanta Pharma Ltd.

30 Jan 2026

3014.90

2.24%

Execution drives earnings beat

buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) posted a better-than-expected financial performance in 3QFY26, with 5%/7%/5% beat on revenue/EBITDA/PAT. AJP saw superior execution in Africa, US and domestic formulation (DF), which was offset to some extent by subdued performance in Asia.

Ajanta Pharma Ltd. is trading above all available SMAs

Ajanta Pharma Ltd.

29 Dec 2025

3014.90

2.24%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Promoters pledged 2.01% of shares in last quarter. Total pledge stands at 17.29% of promoter holdings

Ajanta Pharma Ltd.

04 Nov 2025

3014.90

2.24%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...

Ajanta Pharma Ltd. has an average target of 3120.83 from 6 brokers.

Ajanta Pharma Ltd.

03 Nov 2025

3014.90

2.24%

Ajanta Pharma (HOLD): US generic sales growth weighs on margins

Hold: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 1%/-8%/7% above our estimates. EBITDA margin reported 230 bps below estimates at 24.2%, Adj forex at 27%

Promoters pledged 2.01% of shares in last quarter. Total pledge stands at 17.29% of promoter holdings

Ajanta Pharma Ltd.

03 Nov 2025

3014.90

2.24%

In-line 2Q; growth led by DF/US generics

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP)’s 2QFY26 revenue was slightly above our expectation (3.5% beat). EBITDA and PAT were largely in line and grew at a lower rate compared to revenue growth for the quarter.